Benitec Biopharma Limited (BNTC) Receiving Somewhat Positive Press Coverage, Study Shows
Media stories about Benitec Biopharma Limited (NASDAQ:BNTC) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Benitec Biopharma Limited earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.0523223339299 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Benitec Biopharma Limited (NASDAQ BNTC) opened at 2.0556 on Thursday. The company has a 50-day moving average price of $2.11 and a 200-day moving average price of $2.35. The company’s market cap is $21.08 million. Benitec Biopharma Limited has a 1-year low of $1.30 and a 1-year high of $5.48.
BNTC has been the topic of a number of research analyst reports. Maxim Group reissued a “hold” rating on shares of Benitec Biopharma Limited in a research note on Wednesday, May 31st. ValuEngine cut Benitec Biopharma Limited from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th.
ILLEGAL ACTIVITY WARNING: “Benitec Biopharma Limited (BNTC) Receiving Somewhat Positive Press Coverage, Study Shows” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/14/benitec-biopharma-limited-bntc-receiving-somewhat-positive-press-coverage-study-shows.html.
About Benitec Biopharma Limited
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with MarketBeat.com's FREE daily email newsletter.